1. Kirshenbaum MR, Chen SF, Behrens CH, Papp LM, Stafford MP, Sun JH, Beherens DL, Fredericks JR, Polkus SA, Sipple P, Patten AD, Dexter D, Seitz SP, Degan D, VonHoff D, Gross JL: DMP 840, a novel bis-naphthalimide with potent but non-selective tumoricidal activityin vitro. In Press, Cancer Research
2. Czerniak PM, Dexter DL, Dusak BL, Fredericks JR, Gale KC, Gross JL, Jiang JB, Kirshenbaum MR, McRipley RJ, Papp LM, Patten AD, Perrella FW, Seitz SP, Stafford MP, Sun J-H, Sun T, Wuonola MA, VonHoff DP: XB596, a promising bis-naphthalimide anticancer agent. Anticancer Drugs 4:447?457, 1993
3. Jiang JB, Gross JL, Dusak BA: Bis-naphthalenensul-fonamides. A new series of protein kinase C inhibitors which inhibit tumor cell growth. Proc. of NCI-EORTC symposium on new drugs in cancer therapy 6:45, 1989
4. McRipley RJ, Burns-Horwitz PE, Czerniak PM, Diamond RJ, Diamond MA, Miller JLD, Page RJ, Dexter DL, Chen SF, Sun J-H, Behrens CH, Seitz SP, Gross JL: Efficacy of DMP 840: A novel bis-naphthalimide cytotoxic agent with human solid tumors xenograft selectivity. Cancer Res 54:159?164, 1994
5. Houghton PJ, Cheshire PJ, Hallman JC III, Gross JL, McRipley RJ, Sun J-H, Behrens CH, Dexter DL, Houghton JA: Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile and pediatric cancers. Cancer Chemotherapy Pharmacology 33:265?272, 1994